$TYRA News

Wolfe Research Initiates Coverage On Tyra Biosciences with Peer Perform Rating

HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $45 Price Target

Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Tyra Biosciences Q1 EPS $(0.64) Misses $(0.59) Estimate

Tyra Biosciences to Participate in Upcoming Investor Conferences

Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib

Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

Guggenheim Initiates Coverage On Tyra Biosciences with Buy Rating, Announces Price Target of $54

Canaccord Genuity Initiates Coverage On Tyra Biosciences with Buy Rating, Announces Price Target of $50

A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial Progress

Piper Sandler Maintains Overweight on Tyra Biosciences, Raises Price Target to $56

On March 4, 2026, Tyra Biosciences Agreed To Issue And Sell 4,000,000 Shares Of Common Stock To A Large Investment Management Firm At A Purchase Price Of $31.50 Per Share; Co. Expects To Receive $126.0M In Gross Proceeds Upon Settlement, Before Deducting Fees And Other Expenses Payable By It

Did Deeper Losses and Dabogratinib Progress Just Shift Tyra Biosciences' (TYRA) Investment Narrative?

Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Tyra Biosciences Q4 EPS $(0.57) Misses $(0.55) Estimate

Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data

Cantor Fitzgerald Initiates Coverage On Tyra Biosciences with Overweight Rating

Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

Tyra Biosciences To Reveal Poster Presentations At The 2026 ASCO Genitourinary Cancers Symposium

Tyra Biosciences To Reveal Poster Presentations At The 2026 ASCO Genitourinary Cancers Symposium